Not yet recruitingPhase 2NCT07001254

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

Studying Aplastic Anemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Anjali Sharathkumar
Principal Investigator
Anjali Sharathkumar, MD
University of Iowa
Intervention
Romiplostim(drug)
Enrollment
15 enrolled
Eligibility
2-21 years · All sexes
Timeline
2026 – 2031

Study locations (1)

Collaborators

Department of Health and Human Services · Food and Drug Administration (FDA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07001254 on ClinicalTrials.gov

Other trials for Aplastic Anemia

Additional recruiting or active studies for the same condition.

See all trials for Aplastic Anemia →

← Back to all trials